The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | KarMMa-4: ide-cel for newly diagnosed high-risk multiple myeloma
Nina Shah, MD, University of California-San Francisco, San Francisco, CA, introduces the KarMMa-4 trial (NCT04196491), a Phase I trial of idecabtagene vicleucel (ide-cel, bb2121) for newly diagnosed high-risk multiple myeloma. Ide-cel is a B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy which has demonstrated deep, durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma. The primary endpoints of the trial are dose-limiting toxicity and safety. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research funding: Celgene/BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar
Advisory role: GSK, Amgen, Indapta Therapeutics, Sanofi, BMS, CareDx, Kite, Karyopharm
